Chengdu Cosmotek

Chengdu Cosmotek is a clinical-stage biotechnology company headquartered in Chengdu, China, focused on the development of innovative drugs using Targeted Protein Degradation (TPD) technology. The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) platform to develop small molecule degraders for high-value targets in oncology and immunology. Its lead program, a BTK degrader, is designed to overcome resistance issues associated with traditional BTK inhibitors in B-cell malignancies. By targeting undruggable proteins, Chengdu Cosmotek aims to deliver breakthrough therapies for patients with complex diseases. The company's pipeline also includes programs targeting hormone receptors for the treatment of solid tumors.